Abstract: Objective The aim of this study was to compare the antiviral efficacy of tenofovir amibufenamide to tenofovir disoproxil fumarate (TDF) in the treatment of patients with chronic hepatitis B (CHB). Methods 62 patients with CHB were enrolled in our hospital between August 2021 and February 2022, and were randomly divided into group A and group B, with 31 cases in each group, receiving tenofovir amibufenamide or TDF for 48 weeks. Serum HBV DNA loads were detected by real-time fluorescence quantitative PCR, serum HBsAg and HBeAg levels were detected by ELISA, and blood routine and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were obtained to calculate fibrosis index based on 4 factor (FIB-4) and estimated glomerular filtration rate (eGFR). The liver stiffness measurement (LSM) was determined by liver transient elastography. Results At 24 weeks of treatment, serum ALT, AST levels and serum HBV DNA load in group A were (64.3±13.6)IU/L, (61.5±4.0)IU/L and (1.2±0.2)Ig IU/mL, and at the end of 48 week treatment, they were (40.1±3.8)IU/L, (39.4±3.3)IU/L and (0.9±0.2)In IU/mL, all not significantly different compared to [(67.2±3.8)IU/L, (65.3±4.2)IU/L and (1.2±0.3)Ig IU/mL, and (38.4±4.1)IU/L, (42.8±3.9)IU/L and (0.9±0.2)Ig IU/mL, respectively, P<0.05] in group B; the LSM, FIB-4 and eGFR in group A were (7.1±1.7)kPa, (2.0±0.4) and (101.3±7.9)mL/min/1.73 m², and (7.2±1.5)kPa, (1.6±0.3) and (100.9±8.2)mL/min/1.73 m², and they were (7.3±1.6)kPa, (2.2±0.5) and (95.6±8.0)mL/min/1.73 m²(P<0.05), and (7.1±1.6)kPa, (1.6±0.4) and (94.0±7.6)mL/min/1.73 m²(P<0.05), not but eGFR, significantly different compared to in group B. Conclusion The oral administration of tenofovir amibufenamide in the treatment of patients with CHB could obtain the same good antiviral efficacy, but might has less untoward impact on renal functions, and warrants further clinical investigation.

Key words: Hepatitis B, Tenofovir amibufenamide, Tenofovir disoproxil fumarate, Therapy